MagForce enters into preclinical research agreement to investigate NanoTherm(R) therapy in the gastrointestinal cancer field in the USA
MagForce AG / MagForce enters into preclinical research agreement to
investigate NanoTherm@ therapy in the gastrointestinal cancer field in
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
? Goal is to achieve preclinical proof-of-concept in pancreatic and
? First important milestone to set up a clinical development program
with Key Opinion Leaders of the Mayo Clinic and throughout the US
? A previous pilot study conducted at the Charité, Berlin, has shown
feasibility for NanoTherm@ therapy in patients with pancreatic cancer
MagForce AG (Frankfurt, XETRA: MF6), a leading medical device company
in the field of nanomedicine with focus on oncology, announced today
that the Company has entered into a pre-clinical research agreement
with Mayo Clinic (Rochester, MN), a leading US medical center.
Under the terms of the agreement, Mayo Clinic will start a research
program applying MagForce's NanoTherm@ therapy to investigate the
preclinical efficacy of the therapy in pancreatic and liver cancer.
The project will be directed by Dev Mukhopadhyay, Professor of
Biochemistry/Molecular Biology, and the study will be funded by Mayo
Clinic. The goal of the project is to achieve preclinical
proof-of-concept in order to file the clinical development program
supporting the FDA PMA (FDA premarket approval) of the NanoTherm@
therapy in these indications.
"Pancreatic cancer is one of the most aggressive diseases in oncology,
ranking fourth among the tumor related causes of death. It is mostly
recognized in a late and advanced status and consequently called "the
silent killer". Due to the poor overall survival rates and the severe
side effects of chemotherapeutics, the current standard of care, this
disease is an enormous challenge in oncology. With approximately
32,000 new cases annually in the US alone there is a very high medical
need to develop new therapeutic options for the treatment of these
desperate patients," said Prof Dr Hoda Tawfik, Vice President
R&D/Medical Affairs at MagForce. "In a pilot study MagForce could show
the feasibility of the use of its NanoTherm@ therapy in pancreatic
cancer patients with first hints of activity. I am delighted that we
are now teaming up with the highly prestigious cancer center Mayo
Clinic to achieve preclinical proof-of-concept in pancreatic and liver
cancer with our innovative technology. A positive outcome of this new
project would be the first important milestone to set up a clinical
development program in gastrointestinal cancer in cooperation with
medical key opinion leaders throughout the United States," added Prof
Dr Hoda Tawfik.
This research agreement is a significant step in engaging the US
medical community in the development of the NanoTherm@ Therapy," added
Dr Andreas Jordan, Executive Board and Founder of MagForce.
About MagForce AG
MagForce AG is a leading medical technology company in the field of
nanomedicine in oncology. The Company's proprietary, NanoTherm@
therapy, enables the targeted treatment of solid tumors through the
intratumoral generation of heat via activation of magnetic
nanoparticles. NanoTherm@, NanoPlan@, and NanoActivator? are
components of the therapy and have received EU-wide regulatory
approval as medical devices for the treatment of brain tumors.
MagForce, NanoTherm@, NanoPlan@, and NanoActivator? are trademarks of
MagForce AG in select countries. For more information, please visit
About NanoTherm@ Therapy
The NanoTherm@ therapy is a new approach for the local treatment of
solid tumors. The principle of the method is the direct introduction
of magnetic nanoparticles into a tumor and their subsequent heating in
an alternating magnetic field. The water soluble nanoparticles are
extremely small (approximately 15 nanometers in diameter), and contain
an iron oxide core with an aminosilane coating. The particles are
activated by a magnetic field that changes its polarity 100,000 times
per second and heat is produced. Depending on the duration of
treatment and the achieved intratumoral temperatures, the tumor cells
are either directly destroyed (thermal ablation) or sensitized for
concomitant chemo or radiotherapy (hyperthermia). With this new
procedure, it is possible to combat the tumor from the inside out,
thereby sparing surrounding healthy tissue. The nanoparticles remain
in place at the treatment area, allowing for repeat treatments and the
integration of multimodal therapy concepts. NanoTherm@ therapy has
regulatory approval in 27 European countries.
This release may contain forward-looking statements and information
which may be identified by formulations using terms such as "expects",
"aims", "anticipates", "intends", "plans", "believes", "seeks",
"estimates" or "will". Such forward-looking statements are based on
our current expectations and certain assumptions, which may be subject
to a variety of risks and uncertainties. The results actually achieved
by MagForce AG may substantially differ from these forward-looking
statements. MagForce AG assumes no obligation to update these
forward-looking statements or to correct them in case of developments,
which differ from those, anticipated.
MagForce_Press Release_Mayo Clinic_June 22, 2012:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and (ii) they are solely responsible for the content,
accuracy and originality of the information contained therein.
Source: MagForce AG via Thomson Reuters ONE [HUG#1621460]